The Malmberg lab partner in major cancer immunotherapy project
Karl-Johan Malmberg
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
Published in Level 2 journals, first or last author from Oslo University Hospital.
Gjelsvik YM, Myklebust TÅ, Fosså SD, Haug ES, Kvåle R, Ursin G, Johannesen TB(2025) A nationwide, longitudinal collection of patient-reported outcomes from prostate cancer patients and controls Qual Life Res(in press) DOI 10.1007/s11136-025-04017-7, PubMed 40603678
Fleur du Pré M, Kleppa L, Dewan AE, Meling MT, Høydahl LS, Besser HA, Khosla C, Sollid LM(2025) Peyer's patch B cells sample transglutaminase-gluten complexes and drive celiac disease autoimmunity Gastroenterology(in press) DOI 10.1053/j.gastro.2025.06.021, PubMed 40602545
Lindemann K, Berton D, Sehouli J, Christensen RD, Altintas S, Knudsen AØ, Heudel PE, Ataseven B, Vergote I, Lindahl G, Lebreton C, Schochter F, Auranen A, Follana P, Madsen K, Selle F, Petersson KS, Joly F, Braicu EI, Mirza MR(2025) NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer Gynecol Oncol, 199, 79-87(in press) DOI 10.1016/j.ygyno.2025.06.008, PubMed 40592025